EP2941255A4 - Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof - Google Patents

Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof

Info

Publication number
EP2941255A4
EP2941255A4 EP13870018.2A EP13870018A EP2941255A4 EP 2941255 A4 EP2941255 A4 EP 2941255A4 EP 13870018 A EP13870018 A EP 13870018A EP 2941255 A4 EP2941255 A4 EP 2941255A4
Authority
EP
European Patent Office
Prior art keywords
treatment
degraded
organism
symptoms
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13870018.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2941255A1 (en
Inventor
Afif Mahmoud Ghannoum
Brian Vincent Sokol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arms Pharmaceutical LLC
Original Assignee
Arms Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arms Pharmaceutical LLC filed Critical Arms Pharmaceutical LLC
Publication of EP2941255A1 publication Critical patent/EP2941255A1/en
Publication of EP2941255A4 publication Critical patent/EP2941255A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP13870018.2A 2013-01-04 2013-10-25 Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof Ceased EP2941255A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749195P 2013-01-04 2013-01-04
US201361829608P 2013-05-31 2013-05-31
US201361859960P 2013-07-30 2013-07-30
PCT/US2013/066863 WO2014107221A1 (en) 2013-01-04 2013-10-25 Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof

Publications (2)

Publication Number Publication Date
EP2941255A1 EP2941255A1 (en) 2015-11-11
EP2941255A4 true EP2941255A4 (en) 2016-07-06

Family

ID=51062409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13870018.2A Ceased EP2941255A4 (en) 2013-01-04 2013-10-25 Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof

Country Status (3)

Country Link
EP (1) EP2941255A4 (https=)
JP (1) JP6901824B2 (https=)
WO (1) WO2014107221A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145307A1 (en) 2011-04-19 2012-10-26 Brian Sokol Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
EP3687375A4 (en) * 2016-11-21 2022-01-19 Psomagen, Inc. METHOD AND SYSTEM FOR CHARACTERIZING A HEADACHE RELATED CONDITION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749869B1 (en) * 1997-09-26 2004-06-15 Ecolab Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
CA2545117A1 (en) * 2003-11-07 2005-05-26 Viratox, L.L.C. Virucidal activities of a combination of cetylpyridinium chloride and citric acid
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
JP2008535918A (ja) * 2005-04-11 2008-09-04 ナノバイオ コーポレーション 感染性の症状を処置するための四級アンモニウムハライド
US9149429B2 (en) * 2007-11-21 2015-10-06 The Procter & Gamble Company Preparations, methods and kits useful for the treatment of cough
WO2012145307A1 (en) * 2011-04-19 2012-10-26 Brian Sokol Method of inhibiting harmful microorganisms and barrier-forming composition therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP2941255A1 (en) 2015-11-11
JP6901824B2 (ja) 2021-07-14
JP2016504381A (ja) 2016-02-12
WO2014107221A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
EP3383411C0 (en) SUB-MITOCHONDRIAL PARTICLES FOR USE IN THE TREATMENT OF METABOLIC DISEASES
EP3313402C0 (en) VMAT2 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR DISORDERS
EP3251666C0 (en) METHOD FOR TREATING NEUROLOGICAL TRAUMA
EP3365062C0 (en) METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY
EP3639853C0 (en) USE OF 4D SEMAPHORIN BINDING MOLECULES TO TREAT NEURODEGENERATIVE DISORDERS
EP3524258C0 (en) METHODS OF TREATING CHRONIC DISORDERS USING COMPLEMENT INHIBITORS
EP3693046C0 (en) PATIENT INTERFACE SYSTEM FOR THE TREATMENT OF RESPIRATORY DISORDERS
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
EP3193862C0 (en) TOPICAL COMPOSITION OF CANNABINOIDS FOR THE TREATMENT OF ARTHRITIS PAIN
EP2943189A4 (en) Methods and comp0stions for treatment of demyelinating diseases
EP3871664C0 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES OR DISORDERS USING SUSTAINED RELEASE NITRIC OXIDE SOLUTIONS
EP4088724C0 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS
EP2850195A4 (en) METHODS AND COMPOSITIONS FOR TREATING AMYLOID DEPOSITS
EP2891494A4 (en) Method for administering hypnotic/sedative agent
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
EP3212228C0 (en) MARAVIROC ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER
EP2544703A4 (en) METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS
EP3741747C0 (en) METHOD FOR PREVENTION AND/OR TREATMENT OF ANXIETY
EP3177311C0 (en) COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA
EP3190886C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
EP2718255A4 (en) QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
EP2825185C0 (en) NEW METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
IL257764B (en) Methods for treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GHANNOUM, AFIF, MAHMOUD

Inventor name: SOKOL, BRIAN, VINCENT

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160608

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/736 20060101AFI20160602BHEP

Ipc: A61K 31/155 20060101ALI20160602BHEP

Ipc: A61P 31/00 20060101ALI20160602BHEP

Ipc: A61K 31/047 20060101ALI20160602BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180226

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20220604